Fulgent Genetics Inc. (FLGT)
$16.55
$-3.66
(-18.11%)
As on 31-Jul-2026 16:00EDT
Market cap
$470 Mln
Revenue (TTM)
$324 Mln
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.1 %
-
ROCE
-- %
-
Industry P/E
46.56
-
EV/EBITDA
2.3
-
Debt to Equity
0
-
Book Value
$36.4
-
EPS
$--
-
Face value
--
-
Shares outstanding
28,400,623
10 Years Aggregate
CFO
$964.94 Mln
EBITDA
$540.57 Mln
Net Profit
$269.46 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Fulgent Genetics (FLGT)
| -37.0 | -19.4 | 11.8 | -5.4 | -24.6 | -29.1 | -- |
|
BSE Sensex
| -7.8 | 1.8 | 0.8 | -4.2 | 5.7 | 8.2 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Fulgent Genetics (FLGT)
| 42.2 | -35.9 | -2.9 | -70.4 | 93.1 | 303.9 | 306.9 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Fulgent Genetics (FLGT)
|
16.6 | 470.0 | 323.9 | -84.4 | -18.9 | -7.9 | -- | 0.5 |
| 29.6 | 2,757.6 | 3,367.7 | -1,126.2 | -26.1 | -57.5 | -- | 1.4 | |
| 532.3 | 7,065.1 | 2,595.0 | 275.0 | 14.1 | 30.4 | 26.8 | 8.5 | |
| 2.8 | 393.4 | 22,413.0 | -300.0 | 19.4 | -- | 1.5 | 0.5 | |
| 4.9 | 70.7 | 253.5 | -21.6 | -0.8 | -21 | -- | 0.8 | |
| 15.3 | 1,964.4 | 766.3 | -51.9 | -6.9 | -6.4 | -- | 2.5 | |
| 1.3 | 985.2 | 587.9 | -72.9 | -6.8 | -5.9 | -- | 0.8 | |
| 23.0 | 3,449.6 | 5,693.5 | 209.6 | 6.0 | 16.2 | 17.4 | 2.7 | |
| 6.7 | 1,195.3 | 2,489.5 | -177.4 | -6.4 | -13.2 | -- | 1.2 | |
| 178.2 | 10,383.6 | 5,486.7 | 378.7 | 9.2 | 16.2 | 27.9 | 4.3 |
Shareholding Pattern
View DetailsAbout Fulgent Genetics (FLGT)
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic... testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California. Read more
-
Chairman & CEO
Mr. Ming Hsieh
-
Chairman & CEO
Mr. Ming Hsieh
-
Headquarters
El Monte, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Fulgent Genetics (FLGT)
What is the current share price of Fulgent Genetics Inc (FLGT) Today?
The share price of Fulgent Genetics Inc (FLGT) is $16.55 (NASDAQ) as of 31-Jul-2026 16:00 EDT. Fulgent Genetics Inc (FLGT) has given a return of -24.61% in the last 3 years.
What is the current PB & PE ratio of Fulgent Genetics Inc (FLGT)?
Since, TTM earnings of Fulgent Genetics Inc (FLGT) is negative, P/E ratio is not available.
The P/B ratio of Fulgent Genetics Inc (FLGT) is 0.47 times as on 31-Jul-2026, a 86 discount to its peers’ median range of 3.44 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-13.46
|
0.73
|
|
2024
|
-12.97
|
0.49
|
|
2023
|
-5.17
|
0.76
|
|
2022
|
6.44
|
0.73
|
|
2021
|
29.89
|
2.69
|
What is the 52 Week High and Low of Fulgent Genetics Inc (FLGT)?
The 52-week high and low of Fulgent Genetics Inc (FLGT) are Rs 31.04 and Rs 13.46 as of 02-Aug-2026.
What is the market cap of Fulgent Genetics Inc (FLGT)?
Fulgent Genetics Inc (FLGT) has a market capitalisation of $ 470 Mln as on 31-Jul-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Fulgent Genetics Inc (FLGT)?
Before investing in Fulgent Genetics Inc (FLGT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.